Clinical and economic impact of a diabetes clinical pharmacy service program in a university and primary care-based collaboration model

Journal of the American Pharmacists Association

Volumn 49, Issue 2, 2009, Pages 200-208

  Monte, Scott V ^a,b   Slazak, Erin M ^a   Albanese, Nicole Paolini ^a   Adelman, Martin ^b   Rao, Gauri ^a   Paladino, Joseph A ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CPL Associates LLC   (United States)

Author keywords

Clinical pharmacy services; Health care costs; Health outcomes; MedSense; Quality improvement strategies; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BLOOD; COOPERATION; ECONOMICS; EDUCATION; GLUCOSE BLOOD LEVEL; GROUP PRACTICE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL PHARMACY; HUMAN; LONGITUDINAL STUDY; MEDICATION THERAPY MANAGEMENT; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACOLOGY; PRIMARY HEALTH CARE; STANDARD; STATISTICAL MODEL; UNITED STATES; UNIVERSITY;

BLOOD GLUCOSE; COOPERATIVE BEHAVIOR; DIABETES MELLITUS, TYPE 2; GROUP PRACTICE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LONGITUDINAL STUDIES; MANAGED CARE PROGRAMS; MEDICATION THERAPY MANAGEMENT; MODELS, ECONOMIC; NEW YORK; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOLOGY; PHARMACY SERVICE, HOSPITAL; PRIMARY HEALTH CARE; UNIVERSITIES;

EID: 67449086077     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.08160     Document Type: Article

References (33)

1. UK Prospective Diabetes Study Group (UKPDS). Intensive bloodglucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2008;31(suppl 1):S12-S54.
5. Saydah S, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.
6. Cranor C, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
7. U.S. Department of Labor Bureau of Labor Statistics. Medical care consumer price index. Accessed at www.bls.gov/cpi/home.htm, October 1, 2008.
8. Fera T, Bluml BM, Ellis WM, et al. The Diabetes Ten City Challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc. 2008;48:181-90.
9. Wubben D, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28:421-36.
10. Clifford RM, Batty KT, Davis TM, et al. A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract. 2002;10:85-90.
11. Davidson M, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Qual. 2000;15:137-42.
12. Irons B, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002;22:1294-300.
13. Kelly C, Rodgers P. Implementation and evaluation of a pharmacist-managed diabetes service. J Manag Care Pharm. 2006;6:488-93.
14. Martin O, Wu WC, Schleinitz MD, et al. Effectiveness of pharmacist-coordinated care to reduce cardiovascular risk factors in patients with diabetes mellitus [online exclusive abstract]. Circulation. 2004;109:e121. Available at http://circ.ahajournals.org/cgi/reprint/09/7/e71.pdf.
15. Shane-McWhorter L, Oderda GM. Providing diabetes education and care to underserved patients in a collaborative practice at a Utah community health center. Pharmacotherapy. 2005;25:96-109.
16. Vivian E. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22:1533-40.
17. Armour C, Taylor SJ, Hourihan F, et al. Implementation and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc. 2004;44:455-66.
18. Choe H, Mitrovich S, Dubay D, et al. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253-60.
19. Clifford R, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle diabetes study. Diabetes Care. 2005;28:771-6.
20. Fornos J, Andres NF, Andres JC, et al. A pharmacotherapy follow-up program in patients with type 2 diabetes in community pharmacies in Spain. Pharm World Sci. 2006;28:65-72.
21. Gong C, Hasson NK, Lum BL. Impact of a diabetes disease management clinic on total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Manag Care Pharm 1999;5:511-15.
22. Guirguis L, Johnson JA, Farris KB, et al. A pilot study to evaluate the role of pharmacists as certified diabetes educators on the clinical and humanistic outcomes of people with diabetes. Can J Diab Care. 2001;25:266-76.
23. Hogan E, Leal S, Slack M, Apgar D. Comparison of pharmacist-led collaborative drug therapy management to standard physician provided therapy for type 2 diabetes mellitus. Presented at: Midyear Clinical Meeting of the American Society of Health-Systems Pharmacists, Las Vegas, NV, December 4-8, 2005.
24. Jaber L, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30:238-43.
25. Krass I, Taylor SJ, McInman A, Armour CL. The pharmacists' role in continuity of care in type 2 diabetes: an evaluation of a model. J Pharm Technol. 2006;22:3-8.
26. Krass I, Armour CL, Mitchell B, et al. The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24:677-83.
27. Leung W, So WY, Tong PC, et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy [online exclusive article]. Am J Med. 2005;118:1414:e21-7. Available athttp://dx.doi.org/10.1016/j.amjmed.2005.07.050.
28. Odegard P, Goo A, Hummel J, et al. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39:433-40.
29. Rothman R, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005;118:276-84.
30. Scott D, Boyd ST, Stephan M, et al. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63:2116-22.
31. Gaede P, Pederson O. Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes. Ann Med. 2004;36:355-66.
32. Jerums G, MacIsaac, RJ. Treatment of microalbuminuria in patients with type 2 diabetes mellitus. Treat Endocrinol. 2002;1:163-73.
33. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes mellitus. N Engl J Med. 2008;358:2545-59.